Kumar Subodh, Kumar Hansraj, Lahon Joonmoni, Saikia Dibyajyoti
Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, India.
Department of Pharmacology, All India Institute of Medical Sciences, Guwahati, India.
Med Pharm Rep. 2024 Jul;97(3):243-248. doi: 10.15386/mpr-2641. Epub 2024 Jul 30.
COVID-19 pandemic has taught many lessons regarding drug discovery and development. This review covers these aspects of drug discovery and research for COVID-19 which might be used as a tool for future. It summarizes the positives such as progresses in antiviral drug discovery, drug repurposing, adaptations of clinical trial and its regulations, as well as the negative points such as the need to develop more collaboration among stakeholders and future directions. It also discusses the benefits and limitations of finding new indications for existing drugs, and the lessons learned regarding rigorous and robust clinical trials, pharmacokinetic/pharmacodynamic modelling, as well as combination therapy. The pandemic has also revealed some gaps regarding global collaboration and coordination, data sharing and transparency and equitable distribution. Finally, the review enumerates the future directions and implications of drug discovery and research for COVID-19 and other infectious diseases such as preparedness and resilience, interdisciplinary and integrative approaches, diversity and inclusion, and personalized and precision medicine.
新冠疫情在药物发现与开发方面给我们带来了许多教训。本综述涵盖了新冠病毒药物发现与研究的这些方面，这些内容可能会成为未来的一种工具。它总结了积极方面，如抗病毒药物发现的进展、药物再利用、临床试验及其法规的调整，以及消极方面，如利益相关者之间需要加强合作以及未来方向。它还讨论了为现有药物寻找新适应症的益处和局限性，以及在严格且稳健的临床试验、药代动力学/药效学建模和联合治疗方面所吸取的经验教训。疫情还揭示了在全球合作与协调、数据共享与透明度以及公平分配方面存在的一些差距。最后，本综述列举了新冠病毒药物发现与研究以及其他传染病的未来方向和启示，如防范与恢复能力、跨学科与综合方法、多样性与包容性以及个性化与精准医学。
